Peregrine and Affitech to collborate on developing antibodies.Peregrine Pharmaceuticals, Inc (Tustin, CA) and Affitech AS (Oslo, Norway) announced that they will collaborate on the production of human antibodies for Peregrine's Vascular Targeting Agent (VTA VTA Valley Transportation Authority (San Jose, California)
VTA Ventral Tegmental Area
VTA Vacuum Triode Amplifier
VTA VFR Terminal Area
VTA Martha's Vineyard Transit Authority (Massachusetts) ) and anti-angiogenesis programs. In this collaboration, Peregrine will provide targets and Affitech will apply its high-quality human antibody libraries and its proprietary discovery and screening technologies, including its unique AffiScreen platform, to generate a panel of fully human antibodies against the targets. The agreement allows flexibility for the development of any clinical candidates that are generated, including joint development, internal development at Peregrine or Affitech, or out-licensing to a third party. Details of the financial terms were not disclosed.
"We are very pleased to enter into this collaboration with Affitech to expand our VTA and anti-angiogenesis programs," stated Steven King Steven King is the name of:
1. an agent that mediates a specific effect.
2. an organ that produces an effect in response to nerve stimulation. functions."
Commenting on the collaboration, Dr. Ole Jorgen Marvik, CEO of Affitech said, "This is a very significant partnership for us, and we are excited to be able to enter into this deal, especially because of Peregrine's dedicated research and development efforts in anti-angiogenesis and Vascular Targeting Agent programs." Dr. Marvik further stated, "This is our third collaboration deal that we have secured in the past two months and all of them are in the oncology field. Given the general success of monoclonal antibodies in the cancer area and in line with Affitech's strategies and ambition to build a pipeline of successful anti-cancer antibody products, we confidently look forward to leverage our validated technology together with Peregrine's patented targets, as well as their long-standing expertise in the development of tumor targeting agents."
Affitech is a human antibody therapeutics company based in Norway, having its United States subsidiary in the San Francisco Bay Area “Bay Area” redirects here. For other uses, see Bay Area (disambiguation).
The San Francisco Bay Area, colloquially known as the Bay Area or The Bay . The company's primary focus is in the discovery and development of human therapeutic antibodies for cancer and infectious diseases. Affitech is the exclusive worldwide patent holder of the phagemid system of antibody and antibody fragments. Additionally, the company has recently implemented a pair of completely novel and exclusive technologies for efficient and rapid discovery of antibodies for therapeutic use. These include an in vitro in vitro /in vi·tro/ (in ve´tro) [L.] within a glass; observable in a test tube; in an artificial environment.
In an artificial environment outside a living organism. selection platform, and its Patient Library/AffiScreen antibody screening technology that utilizes antibody repertoires from patients suffering from cancer and infectious diseases. Affitech's business strategy is to generate short-term revenue through customer-based projects and out-licensing of technology assets and early stage products, and in addition to build a proprietary product pipeline through collaborations and partnership.
Peregrine is a biopharmaceutical company focused on the development, commercialization and licensing of unique technologies for the treatment of cancer, primarily based on three collateral targeting technologies. Peregrine's Tumor Necrosis tumor necrosis Death of tumor tissue, a common event in aggressive CAs in which the tumor rapidly outgrows its blood supply, resulting in tumor cell death. Cf Apoptosis. Therapy, Vasopermeation Enhancement vasopermeation enhancement Oncology An investigational therapy that ↑ up to 3-fold CA cell uptake of chemotherapeutics Agents, and Vascular Targeting Agents technologies target cell structures and cell types that are common among solid tumor cancers, giving them broad applicability across various tumor types. The company has received approval from the FDA FDA
Food and Drug Administration
n.pr See Food and Drug Administration.
n.pr the abbreviation for the Food and Drug Administration. to start a Cotara Phase III clinical trial Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the for brain cancer. Cotara is also being studied in a Phase I trial for colorectal, pancreas, soft tissue sarcoma soft tissue sarcoma Oncology A sarcoma that arises in muscle, fat, fibrous tissue, blood vessels, or other supporting tissues. See Sarcoma.
Soft tissue sarcoma staging
I A and biliary cancers at Stanford University. The company is focused on licensing collaborations for all of its technologies under development. The company's Oncolym technology to treat non-Hodgkin's B-cell lymphoma in Phase I/II of development is available for licensing. The company operates a cGMP contract manufacturing facility for monoclonal antibodies and recombinant proteins through its wholly owned subsidiary Wholly Owned Subsidiary
A subsidiary whose parent company owns 100% of its common stock.
In other words, the parent company owns the company outright and there are no minority owners. Avid Bioservices.
Peregrine Pharmaceuticals, Inc.